wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47807650-DED7CF1E-D157-48E4-A353-EA3C293A34D9
Q47807650-DED7CF1E-D157-48E4-A353-EA3C293A34D9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47807650-DED7CF1E-D157-48E4-A353-EA3C293A34D9
Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.
P2860
Q47807650-DED7CF1E-D157-48E4-A353-EA3C293A34D9
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47807650-DED7CF1E-D157-48E4-A353-EA3C293A34D9
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
81f6b8066562823e3930a2241215e254911e407e
P2860
A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy.